Abbvie Inc
Change company Symbol lookup
Select an option...
ABBV Abbvie Inc
IMNM Immunome Inc
SNMP Evolve Transition Infrastructure LP
BIOC Biocept Inc
BOXD Boxed Inc
EHTH eHealth Inc
SNCE Science 37 Holdings Inc
ONL Orion Office Reit Inc
BKKT Bakkt Holdings Inc
MOGU Mogu Inc

Health Care : Biotechnology | Large Cap Value
Company profile

AbbVie Inc. (AbbVie) is a diversified research-based biopharmaceutical company. The Company is engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers products in various therapeutic categories, including immunology products, which include Humira, Skyrizi and Rinvoq; oncology products, which include Imbruvica and Venclexta/Venclyxto; aesthetics products that include Botox Cosmetic, The Juvederm Collection of Fillers and others; neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; eye care products, which consists of Lumigan/Ganfort, Alphagan/Combigan and Restasis, and other key products, which include Mavyret/Maviret, Creon, Lupron, Linzess/Constella and Synthroid. Its products are sold to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from the AbbVie-owned distribution centers and public warehouses.

Day's Change
1.04 (0.67%)
B/A Size
Day's High
Day's Low

Today's volume of 1,064,664 shares is on pace to be much lighter than ABBV's 10-day average volume of 9,638,539 shares.


Allergan Aesthetics takes a 360°approach to non-surgical aesthetic treatments to improve patient outcomes with expert-led medical education symposium at IMCAS 2023

11:42 am ET January 25, 2023 (PR Newswire) Print

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today unveiled at the 24th International Master Course on Aging Science (IMCAS) World Congress its immersive experience 'Discover your 360°'. This is a customer centric approach, which supports continued innovation and provides cutting-edge products and technologies to help practitioners and patients' aesthetics needs today and for the future.

As part of a 360° offering, Allergan Aesthetics aims to fulfil practitioners' business goals as well as continue to provide world class medical education. In its recently launched global trends report, Future of Aesthetics, which explores how the Aesthetics industry is being shaped by social and cultural shifts, Allergan Aesthetics anticipates how industry behaviours will evolve and thus meet the needs of practitioners and patients. Themes such as Gender Inclusive Beauty, the New Masculine and The End of Aging will be discussed at the Allergan Medical Institute(R) (AMI) hosted symposium, interactive booth, and during the company's participation in three industry panels.

World-renowned plastic and cosmetic surgeon Dr. Arthur Swift will launch this year's sponsored symposia with 'New perspectives for a changing world' - looking at how a 360° approach to products, practitioners and practice can enable treatment of a full spectrum of patients. This will take place on January 28 at 10:30-12:30 in the Amphi Bleu room, Level 2, Palais des Congrès,Paris. He will also conclude the symposia with a review of Dr. Reha Yavuzer's live injection demonstration on redefining masculinity.

Specialist plastic surgeon Dr. Steven Liew will look at the evolving patient and provide his guide to principles, products and patients in a session exploring tailor made patient journeys. Dr. Marva Safa and Dr. Patricia Ogilvie's session will explore new cultural conversations on individuality and fluidity - as 78 million people identify as neither male nor female1, a key insight to consider before treatment.

At the Allergan Aesthetics booth - [N227, Level 2, Palais des Congrès Paris, January 26-28 2023] - the 'Meet the Experts' sessions, each lasting 360 seconds, provides delegates with the opportunity to gain direct insights from thought leaders in aesthetic medicine in a highly engaging and interactive format. Six speakers will deliver a total of 17 sessions across the three days.

Commenting on the congress, Jason Smith, SVP, International Allergan Aesthetics said: "With our vast product portfolio in the aesthetics space we are excited to support the educational journey of our practitioners at IMCAS. We want to showcase Allergan Aesthetics' dedication to excellence in clinical practice through our 'Discover your 360°' symposium. This comprehensive initiativehas been designed from the ground up to improve patient outcomes and we hope these latest techniques are helpful for surgeons and aesthetic physicians across the world."

As well as the symposium and booth activity, Allergan Aesthetics will also take part in three exciting expert panels: one on emerging toxins, a filler panel event, and the economic tribune on Friday, 27 January 14:00pm (BST), where Jason Smith will present.


Notes to Editors:

About Allergan Aesthetics

At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information,

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us Follow@abbvieonTwitter,Facebook,Instagram,YouTubeandLinkedIn.

1Ipsos Global Survey, June 2021 Veeva Ref: REF-65469

View original content:


comtex tracking


Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.